Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.07
+0.39 (2.85%)
At close: May 27, 2026, 4:00 PM EDT
14.05
-0.02 (-0.14%)
After-hours: May 27, 2026, 7:32 PM EDT
Amylyx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
1.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.53B |
| Perrigo Company | 4.18B |
| Phibro Animal Health | 1.50B |
| ANI Pharmaceuticals | 923.71M |
| BioCryst Pharmaceuticals | 885.72M |
| Evotec SE | 859.03M |
| Collegium Pharmaceutical | 796.33M |
| Alvotech | 562.04M |
AMLX News
- 12 days ago - Amylyx announces publication of Phase 2 open-label HELIOS trial data - TheFly
- 12 days ago - Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation - Business Wire
- 13 days ago - Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus - MarketBeat
- 14 days ago - Amylyx Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 20 days ago - Amylyx sees cash runway into 2028 - TheFly
- 20 days ago - Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 20 days ago - Amylyx Pharmaceuticals Earnings release: Q1 2026 - Filings
- 20 days ago - Amylyx Pharmaceuticals Quarterly report: Q1 2026 - Filings